Corline Biomedical AB engages in the research, development, and commercialization of heparin based solutions. Its products intend to improve kidney transplantation, cell therapies, and applications. The firm operates under the following trademarks: CHC, Renaparin, Cytoparin, and CHS. The company was founded in 1991 and is headquartered in Uppsala, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company